Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
在市場風起雲湧和不確定時期，即使市場處於歷史最高點，許多投資者也會轉向股息率高的股票。這些公司通常具有高自由現金流並以高股息派息回報股東。
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Benzinga的讀者可以查看我們的分析師股票評級頁面，查看最新的分析師對他們最喜愛的股票的看法。交易員可以瀏覽Benzinga的廣泛分析師評級數據庫，包括按分析師準確性排序。
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
以下是醫療保健板塊三隻高收益股票最準確的分析師評級。
Gilead Sciences, Inc. (NASDAQ:GILD)
吉利德科學股份有限公司（納斯達克股票代碼：GILD）
- Dividend Yield: 4.47%
- Baird analyst Brian Skorney maintained a Neutral rating with a price target of $80 on June 20. This analyst has an accuracy rate of 64%.
- RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating with a price target of $74 on June 14. This analyst has an accuracy rate of 66%.
- Recent News: On June 26, Gilead Sciences Canada announced Phase 3 PURPOSE 1 Trial results.
- Benzinga Pro's real-time newsfeed alerted to latest GILD's news
- 股息收益率：4.47%
- 貝爾德分析師布賴恩·斯科尼（Brian Skorney）於6月20日維持了中立評級，目標價爲80美元。該分析師的準確率爲64%。
- RBC資本分析師布賴恩·亞伯拉罕斯（Brian Abrahams）於6月14日重申板塊表現評級，目標價爲74美元。該分析師的準確率爲66%。
- 最近的資訊：6月26日，吉利德科學加拿大宣佈了3期PURPOSE 1試驗結果。
- Benzinga Pro的即時新聞提醒了最新的GILD資訊。
CVS Health Corporation (NYSE:CVS)
西維斯健康公司（紐約證券交易所股票代碼：CVS）
- Dividend Yield: 4.56%
- JP Morgan analyst Lisa Gill maintained an Overweight rating and cut the price target from $101 to $86 on May 30. This analyst has an accuracy rate of 60%.
- Argus Research analyst Chris Graja maintained a Buy rating and slashed the price target from $100 to $80 on May 8. This analyst has an accuracy rate of 69%.
- Recent News: On May 1, CVS Health reported first-quarter sales of $88.4 billion, up 3.7% year over year. It missed the consensus of $89.21 billion.
- Benzinga Pro's charting tool helped identify the trend in CVS stock.
- 股息收益率：4.56%
- JP摩根分析師Lisa Gill於5月30日維持超配評級，將價格目標從101美元下調至86美元。該分析師的準確率爲60%。
- 雅運股份研究分析師Chris Graja於5月8日維持買入評級，將價格目標從100美元下調至80美元。該分析師的準確率爲69%。
- 最近的資訊：5月1日，西維斯健康報告了第一季度銷售額爲884億美元，同比增長3.7%。它未能達到89.21億美元的共識。
- Benzinga Pro的圖表工具幫助識別了CVS股票的趨勢。
Johnson & Johnson (NYSE:JNJ)
強生公司（紐交所股票代碼：JNJ）
- Dividend Yield: 3.40%
- Cantor Fitzgerald analyst LouiseChenreiterated an Overweight rating with a price target of $215 on June 25. This analyst has an accuracy rate of 69%.
- B of A Securities analyst GeoffMeachammaintained a Neutral rating and cut the price target from $180 to $170 on April 17. This analyst has an accuracy rate of 62%.
- Recent News: On June 21, Johnson & Johnson announced that it has successfully completed the acquisition of Proteologix, Inc.
- Benzinga Pro's signals feature notified of a potential breakout in JNJ's shares.
- 股息收益率：3.40%
- 康泰納仕分析師路易絲·陳（Louise Chen）於6月25日重申超配評級，目標價爲215美元。該分析師的準確率爲69%。
- B of A證券分析師GeoffMeacham於4月17日維持中立評級，將價格目標從180美元下調至170美元。該分析師的準確率爲62%。
- 最近的資訊：6月21日，強生公司宣佈已成功完成對Proteologix公司的收購。
- Benzinga Pro的信號功能通知了JNJ股票潛在的突破。
Read More: How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro
閱讀更多：如何使用Benzinga Pro查找分紅股票：掃描、分析和捕捉
譯文內容由第三人軟體翻譯。